EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
What is the ‘know-how gap’ problem and how might it impact scaling up production...
This entire article is also available as a PDF by clicking here.
1. Introduction.
How relevant are concerns about intellectual property rights causing problems for...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
Dolutegravir Patent Licences Can Provide Access To All
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...
The Expanding Reach of the European Patent Office. Good for Health?
The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...
Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...
On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...
New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...
The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...
Price, profit and the Covid-19 health technology pool: The example of remdesivir
We cannot yet know the precise trajectory of the Covid-19 pandemic, nor which therapies or vaccines will eventually prove most effective in its treatment...
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...